Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance

Stewart G. Albert, Marc J. Shapiro, Wendy W. Brown, Henry Goodgold, Darryl Zuckerman, Rodney Durham, Morton Kern, James Fletcher, Michael Wolverson, E. Sharon Plummer, Arthur E. Baue

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. This study was devised to develop a method of measuring the acute effects of radiocontrast media on renal function and assessing the relationship of the dose of radiocontrast media infused with the incidence of radiocontrast-induced renal failure. In addition, the drug adenosine phosphate-magnesium chloride (ATP-MgCl2) was evaluated as a renoprotective agent. METHODS. Eighteen patients with pre-existing renal impairment, (serum creatinine greater than 133 µmol/L) were randomized to receive a continuous infusion of ATP-MgCI2 or placebo before and during a radiocontrast procedure. Subjects were monitored with daily serum creatinine and with radionuclide renal clearance studies at baseline, during, and 24 hours after the radiocontrast procedure. RESULTS. There was an initial deterioration in renal clearance in the entire study group (from 44.2 ± 4.6 to 32.6 ± 3.9 mL/min, P = .001) which was independent of the dose of radiocontrast infused. There was a persistent deterioration in renal clearance only in those who received greater than 135 mL of contrast media (from 48.6 ± 7.8 to 37.1 ± 3.9 mL/min, P = .05). There also was an increase in serum creatinine that persisted only in those subjects who received greater than 135 mL of contrast media (230 ± 27 to 283 ± 44 pmol/L, P = .01). CONCLUSION. Persistent deterioration in renal function after radiocontrast administration appears to be dose-dependent and is not prevented by the use of ATP-MgCl2. Radionuclide techniques are useful in monitoring acute changes in renal function during radiocontrast procedures and may be of value in assessing renal impairment in future intervention studies.

Original languageEnglish (US)
Pages (from-to)618-623
Number of pages6
JournalInvestigative Radiology
Volume29
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Radioisotopes
Kidney
Contrast Media
Creatinine
Adenosine Triphosphate
Serum
Magnesium Chloride
Adenine Nucleotides
Renal Insufficiency
Placebos
Incidence
Pharmaceutical Preparations

Keywords

  • Adenosine triphosphate-magnesium chloride
  • Contrast nephropathy
  • Radionuclide renal clearance

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Albert, S. G., Shapiro, M. J., Brown, W. W., Goodgold, H., Zuckerman, D., Durham, R., ... Baue, A. E. (1994). Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Investigative Radiology, 29(6), 618-623.

Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. / Albert, Stewart G.; Shapiro, Marc J.; Brown, Wendy W.; Goodgold, Henry; Zuckerman, Darryl; Durham, Rodney; Kern, Morton; Fletcher, James; Wolverson, Michael; Plummer, E. Sharon; Baue, Arthur E.

In: Investigative Radiology, Vol. 29, No. 6, 1994, p. 618-623.

Research output: Contribution to journalArticle

Albert, SG, Shapiro, MJ, Brown, WW, Goodgold, H, Zuckerman, D, Durham, R, Kern, M, Fletcher, J, Wolverson, M, Plummer, ES & Baue, AE 1994, 'Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance', Investigative Radiology, vol. 29, no. 6, pp. 618-623.
Albert SG, Shapiro MJ, Brown WW, Goodgold H, Zuckerman D, Durham R et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Investigative Radiology. 1994;29(6):618-623.
Albert, Stewart G. ; Shapiro, Marc J. ; Brown, Wendy W. ; Goodgold, Henry ; Zuckerman, Darryl ; Durham, Rodney ; Kern, Morton ; Fletcher, James ; Wolverson, Michael ; Plummer, E. Sharon ; Baue, Arthur E. / Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. In: Investigative Radiology. 1994 ; Vol. 29, No. 6. pp. 618-623.
@article{484dd16c64ec4f56a68e5fc2859230e5,
title = "Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance",
abstract = "RATIONALE AND OBJECTIVES. This study was devised to develop a method of measuring the acute effects of radiocontrast media on renal function and assessing the relationship of the dose of radiocontrast media infused with the incidence of radiocontrast-induced renal failure. In addition, the drug adenosine phosphate-magnesium chloride (ATP-MgCl2) was evaluated as a renoprotective agent. METHODS. Eighteen patients with pre-existing renal impairment, (serum creatinine greater than 133 µmol/L) were randomized to receive a continuous infusion of ATP-MgCI2 or placebo before and during a radiocontrast procedure. Subjects were monitored with daily serum creatinine and with radionuclide renal clearance studies at baseline, during, and 24 hours after the radiocontrast procedure. RESULTS. There was an initial deterioration in renal clearance in the entire study group (from 44.2 ± 4.6 to 32.6 ± 3.9 mL/min, P = .001) which was independent of the dose of radiocontrast infused. There was a persistent deterioration in renal clearance only in those who received greater than 135 mL of contrast media (from 48.6 ± 7.8 to 37.1 ± 3.9 mL/min, P = .05). There also was an increase in serum creatinine that persisted only in those subjects who received greater than 135 mL of contrast media (230 ± 27 to 283 ± 44 pmol/L, P = .01). CONCLUSION. Persistent deterioration in renal function after radiocontrast administration appears to be dose-dependent and is not prevented by the use of ATP-MgCl2. Radionuclide techniques are useful in monitoring acute changes in renal function during radiocontrast procedures and may be of value in assessing renal impairment in future intervention studies.",
keywords = "Adenosine triphosphate-magnesium chloride, Contrast nephropathy, Radionuclide renal clearance",
author = "Albert, {Stewart G.} and Shapiro, {Marc J.} and Brown, {Wendy W.} and Henry Goodgold and Darryl Zuckerman and Rodney Durham and Morton Kern and James Fletcher and Michael Wolverson and Plummer, {E. Sharon} and Baue, {Arthur E.}",
year = "1994",
language = "English (US)",
volume = "29",
pages = "618--623",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance

AU - Albert, Stewart G.

AU - Shapiro, Marc J.

AU - Brown, Wendy W.

AU - Goodgold, Henry

AU - Zuckerman, Darryl

AU - Durham, Rodney

AU - Kern, Morton

AU - Fletcher, James

AU - Wolverson, Michael

AU - Plummer, E. Sharon

AU - Baue, Arthur E.

PY - 1994

Y1 - 1994

N2 - RATIONALE AND OBJECTIVES. This study was devised to develop a method of measuring the acute effects of radiocontrast media on renal function and assessing the relationship of the dose of radiocontrast media infused with the incidence of radiocontrast-induced renal failure. In addition, the drug adenosine phosphate-magnesium chloride (ATP-MgCl2) was evaluated as a renoprotective agent. METHODS. Eighteen patients with pre-existing renal impairment, (serum creatinine greater than 133 µmol/L) were randomized to receive a continuous infusion of ATP-MgCI2 or placebo before and during a radiocontrast procedure. Subjects were monitored with daily serum creatinine and with radionuclide renal clearance studies at baseline, during, and 24 hours after the radiocontrast procedure. RESULTS. There was an initial deterioration in renal clearance in the entire study group (from 44.2 ± 4.6 to 32.6 ± 3.9 mL/min, P = .001) which was independent of the dose of radiocontrast infused. There was a persistent deterioration in renal clearance only in those who received greater than 135 mL of contrast media (from 48.6 ± 7.8 to 37.1 ± 3.9 mL/min, P = .05). There also was an increase in serum creatinine that persisted only in those subjects who received greater than 135 mL of contrast media (230 ± 27 to 283 ± 44 pmol/L, P = .01). CONCLUSION. Persistent deterioration in renal function after radiocontrast administration appears to be dose-dependent and is not prevented by the use of ATP-MgCl2. Radionuclide techniques are useful in monitoring acute changes in renal function during radiocontrast procedures and may be of value in assessing renal impairment in future intervention studies.

AB - RATIONALE AND OBJECTIVES. This study was devised to develop a method of measuring the acute effects of radiocontrast media on renal function and assessing the relationship of the dose of radiocontrast media infused with the incidence of radiocontrast-induced renal failure. In addition, the drug adenosine phosphate-magnesium chloride (ATP-MgCl2) was evaluated as a renoprotective agent. METHODS. Eighteen patients with pre-existing renal impairment, (serum creatinine greater than 133 µmol/L) were randomized to receive a continuous infusion of ATP-MgCI2 or placebo before and during a radiocontrast procedure. Subjects were monitored with daily serum creatinine and with radionuclide renal clearance studies at baseline, during, and 24 hours after the radiocontrast procedure. RESULTS. There was an initial deterioration in renal clearance in the entire study group (from 44.2 ± 4.6 to 32.6 ± 3.9 mL/min, P = .001) which was independent of the dose of radiocontrast infused. There was a persistent deterioration in renal clearance only in those who received greater than 135 mL of contrast media (from 48.6 ± 7.8 to 37.1 ± 3.9 mL/min, P = .05). There also was an increase in serum creatinine that persisted only in those subjects who received greater than 135 mL of contrast media (230 ± 27 to 283 ± 44 pmol/L, P = .01). CONCLUSION. Persistent deterioration in renal function after radiocontrast administration appears to be dose-dependent and is not prevented by the use of ATP-MgCl2. Radionuclide techniques are useful in monitoring acute changes in renal function during radiocontrast procedures and may be of value in assessing renal impairment in future intervention studies.

KW - Adenosine triphosphate-magnesium chloride

KW - Contrast nephropathy

KW - Radionuclide renal clearance

UR - http://www.scopus.com/inward/record.url?scp=0028223540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028223540&partnerID=8YFLogxK

M3 - Article

C2 - 8088970

AN - SCOPUS:0028223540

VL - 29

SP - 618

EP - 623

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 6

ER -